| dc.contributor | 神經科學研究所 | zh_Tw |
| dc.creator (作者) | Chen, Kuan-Yang;Lin, Tsung-Jung;Lin, Chin-Lin;Lee, Hsi-Chang;Wang, Chung-Kwe;Wu, Deng-Chyang | en_US |
| dc.creator (作者) | 陳冠仰 | zh_TW |
| dc.date (日期) | 2015-09 | en_US |
| dc.date.accessioned | 7-八月-2017 17:41:18 (UTC+8) | - |
| dc.date.available | 7-八月-2017 17:41:18 (UTC+8) | - |
| dc.date.issued (上傳時間) | 7-八月-2017 17:41:18 (UTC+8) | - |
| dc.identifier.uri (URI) | http://nccur.lib.nccu.edu.tw/handle/140.119/111651 | - |
| dc.description.abstract (摘要) | AIM: To evaluate the efficacy of sequential vs hybrid therapy in patients with Helicobacter pylori (H. pylori ) infection. METHODS: From March 2013 to May 2014, one hundred and seventy-five H. pylori infected patients who had not been treated for H. pylori before were randomized to receive either sequential therapy (rabeprazole 20 mg and amoxicillin 1 g twice daily for 5 d, followed by rabeprazole 20 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 5 d) or hybrid therapy (rabeprazole 20 mg and amoxicillin 1 g for 7 d, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 d). H. pylori status was confirmed by positive results of both rapid urease test and histology examination or a positive result of culture. Eradication efficacy was assessed by follow-up endoscopy with rapid urease test and histological examination 8 wk after the end of anti-H. pylori therapy, or 13C-urea breath test at least 4 wk after completion of treatment. The primary outcome was H. pylori eradication by intension-to-treat (ITT) and per-protocol (PP) analyses. RESULTS: One hundred and sixty-seven patients (83 patients in the sequential group and 84 patients in the hybrid group) completed the study. The compliance rates were 97.6% and 97.7% for the two groups, respectively. The eradication rate was 78.2% for the sequential group and 92% for the hybrid group by ITT analysis (p = 0.01). The eradication rate was 81.9% for the sequential group and 96.4% for the hybrid group by PP analysis (p = 0.01). Univariate analysis for the clinical and bacterial factors did not identify any risk factors associated with treatment failure. Severe adverse events were observed in 2.3% of patients in the sequential group and 2.4% of those in the hybrid group. CONCLUSION: Due to a grade A (> 95%) success rate for H. pylori eradication by PP analysis, similar compliance and adverse events, hybrid therapy seems to be an appropriate eradication regimen in Taiwan. © The Author(s) 2015. | en_US |
| dc.format.extent | 1066675 bytes | - |
| dc.format.mimetype | application/pdf | - |
| dc.relation (關聯) | World Journal of Gastroenterology, 21(36), 10435-10442 | en_US |
| dc.subject (關鍵詞) | amoxicillin; clarithromycin; metronidazole; rabeprazole; urea c 13; amoxicillin; antiinfective agent; clarithromycin; metronidazole; proton pump inhibitor; rabeprazole; abdominal pain; adult; anorexia; antibiotic resistance; Article; bacterium culture; bitter taste; breath analysis; constipation; controlled study; diarrhea; dizziness; drug efficacy; drug treatment failure; endoscopy; eradication therapy; fatigue; female; follow up; headache; Helicobacter infection; Helicobacter pylori; histology; human; hybrid therapy; intention to treat analysis; major clinical study; male; medication compliance; nausea; patient compliance; prospective study; randomized controlled trial; rapid urease test; rash; risk factor; sequential therapy; side effect; Taiwan; treatment duration; treatment outcome; vomiting; aged; combination drug therapy; comparative study; drug effects; Helicobacter Infections; Helicobacter pylori; microbiology; middle aged; time factor; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans; Intention to Treat Analysis; Male; Metronidazole; Middle Aged; Prospective Studies; Proton Pump Inhibitors; Rabeprazole; Taiwan; Time Factors; Treatment Outcome | en_US |
| dc.title (題名) | Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial | en_US |
| dc.type (資料類型) | article | |
| dc.identifier.doi (DOI) | 10.3748/wjg.v21.i36.10435 | |
| dc.doi.uri (DOI) | http://dx.doi.org/10.3748/wjg.v21.i36.10435 | |
